TransMedics (TMDX) Cash & Equivalents (2018 - 2026)

TransMedics has reported Cash & Equivalents for 9 years, with the latest figure at $461.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 48.87% year-over-year to $461.7 million; the trailing twelve-month figure through Mar 2026 stood at $461.7 million (up 48.87% YoY), and the FY2025 full-year result was $488.4 million, up 45.07% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $461.7 million, down from $488.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $582.2 million in Q2 2023, with the low at $17.9 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $329.2 million, with a median of $350.2 million recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 1816.01% in 2023 and sank 37.69% in 2024.
• Tracing TMDX's Cash & Equivalents over 5 years: stood at $201.2 million in 2022, then soared by 96.25% to $394.8 million in 2023, then retreated by 14.73% to $336.6 million in 2024, then surged by 45.07% to $488.4 million in 2025, then retreated by 5.46% to $461.7 million in 2026.
• The last three Cash & Equivalents figures came in at $461.7 million (Q1 2026), $488.4 million (Q4 2025), and $466.2 million (Q3 2025), per Business Quant data.

Peer Comparison